Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 1, 2009, Pages 256-262

  Karicherla, Priyanka ^a   Hobden, Jeffery A ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; CIPROFLOXACIN; INTERLEUKIN 1BETA; PHOSPHATE BUFFERED SALINE; FURIN; NONAARGININE; OLIGOPEPTIDE;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CORNEA PERFORATION; CYTOKINE PRODUCTION; FEMALE; HISTOPATHOLOGY; KERATITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA KERATITIS; SCORING SYSTEM; ANIMAL; BACTERIAL COUNT; BACTERIAL EYE INFECTION; CORNEA; CORNEA ULCER; DISEASE MODEL; DRUG ANTAGONISM; DRUG COMBINATION; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; PATHOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ANIMALS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; CORNEA; CORNEAL ULCER; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; FEMALE; FURIN; INTERLEUKIN-1BETA; MICE; OLIGOPEPTIDES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 58249087702     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2344     Document Type: Article

References (42)

1. Lyczak JB, Cannon CL, Pier GB. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2000;2:1051-1060.
2. Iglewski BH, Burns RP, Gipson IK. Pathogenesis of corneal damage from Pseudomonas exotoxin A. Invest Ophthalmol Vis Sci. 1977; 16:73-76.
3. Berk RS, Iglewski BH, Hazlett LD. Age-related susceptibility of mice to ocular challenge with Pseudomonas aeruginosa exotoxin A. Infect Immun. 1981;33:90 -94.
4. Hazlett LD, Berk RS, Iglewski BH. Microscopic characterization of ocular damage produced by Pseudomonas aeruginosa toxin A. Infect Immun. 1981;34:1025-1035.
5. Miyazaki S, Matsumoto T, Tateda K, Ohno A, Yamaguchi K. Role of exotoxin A in inducing severe Pseudomonas aeruginosa infections in mice. J Med Microbiol. 1995;43:169-175.
6. Pillar CM, Hobden JA. Pseudomonas aeruginosa exotoxin A and keratitis in mice. Invest Ophthalmol Vis Sci. 2002;43:1437-1444.
7. Ogata M, Chaudhary VK, Pastan I, FitzGerald DJ. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem. 1990;265:20678-20685.
8. Ogata M, Fryling CM, Pastan I, FitzGerald DJ. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem. 1992;267:25396-253401.
9. Yates SP, Jørgensen R, Andersen GR, Merrill AR. Stealth and mimicry by deadly bacterial toxins. Trends Biochem Sci. 2006;31:123-133.
10. Inocencio NM, Moehring JM, Moechring TJ. Furin activates Pseuomonas exotoxin A by specific cleavage in vivo and in vitro. J Biol Chem. 1994;269:31831-31835.
11. Cameron A, Appel J, Houghten RA, Lindberg I. Polyarginines are potent furin inhibitors. J Biol Chem. 2000;275:36741-36749.
12. Sarac MS, Cameron A, Lindberg I. The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun. 2002;70:7136-7139.
13. Kacprzak MM, Peinado JR, Than ME, et al. Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine. J Biol Chem. 2004;279:36788-36794.
14. Kahn CR Young E, Lee IH, Rhim JS. Human corneal epithelial primary cultures and cell lines with extended life span: in vitro model for ocular studies. Invest Ophthalmol Vis Sci. 1993;34: 3429-3441.
15. Amsterdam D. Susceptibility testing of antimicrobials in liquid media. Lorian V, ed. Antibiotics in Laboratory Medicine. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:61-143.
16. Pillai SK, Moellering RC Jr, Eliopoulos GM. Antimicrobial combinations. Lorian V, ed. Antibiotics in Laboratory Medicine. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:365-440.
17. + T cell-dependent keratitis with genetic susceptibility to Pseudomonas aeruginosa ocular infection. J Immunol. 1997;159:6283-6290.
18. Hazlett LD, Moon MM, Strejc M, Berk RS. Evidence for N-acetylmannosamine as an ocular receptor for P. aeruginosa adherence to scarified cornea. Invest Ophthalmol Vis Sci. 1987;28:1978-1985.
19. Hancock REW, Sahl HG. Antimicrobial and host defense peptides as new anti-infective therapeutic agents. Nature BioTechnol. 2006;24:1551-1557.
20. Rudner XL, Kernacki KA, Barrett RP, Hazlett LD. Prolonged elevation of IL-1 in Pseudomonas aeruginosa ocular infection regulates macrophage-inflammatory protein-2 production, polymorphonuclear neutrophil persistence, and corneal perforation. J Immunol. 2000;164:6576-6582.
21. Xue ML, Wakefield D, Willcox MDP, et al. Regulation of MMPs and TIMPs by IL-1β during corneal ulceration and infection. Invest Ophthalmol Vis Sci. 2003;44:2020-2025.
22. Thakur A, Barrett RP, McClellan S, Hazlett LD. Regulation of Pseudomonas aeruginosa corneal infection in IL-1β converting enzyme (ICE, caspase-1) deficient mice. Curr Eye Res. 2004;29: 225-233.
23. Hazlett LD. Corneal response to Pseudomonas aeruginosa infection. Prog Retin Eye Res. 2004;23:1-30.
24. Willcox MDP. Pseudomonas aeruginosa infection and inflammation during contact lens wear: a review. Optom Vis Sci. 2007;84: 273-278.
25. Hazlett LD. Bacterial infections of the cornea (Pseudomonas aeruginosa). Chem Immunol Allergy. 2007;92:185-194.
26. Wilhelmus KR. Indecision about corticosteroids for bacterial keratitis. Opthalmology. 2002;109:835-844.
27. Suwan-Apichon O, Reyes JM, Herretes S, Vedula SS, Chuck RS. Topical corticosteroids as adjunctive therapy for bacterial keratitis. Cochrane Database Syst Rev. 2007;4:CD005430.
28. Kessler E, Israel M, Landshman N, Chechick A, Blumberg S. In vitro inhibition of Pseudomonas aeruginosa elastase by metal-chelating peptide derivatives. Infect Immun. 1982;38:716-723.
29. Kessler E, Spierer A. Inhibition by phosphoramidon of Pseudomonas aeruginosa elastase injected intracorneally in rabbit eyes. Curr Eye Res. 1984;3:1075-1078.
30. Burns FR, Paterson CA, Gray RD, Wells JT. Inhibition of Pseudomonas aeruginosa elastase and Pseudomonas keratitis using a thiol-based peptide. Antimicrob Agents Chemother. 1990;34: 2065-2069.
31. Barletta JP, Angella G, Balch KC, et al. Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor. Invest Ophthalmol Vis Sci. 1996;37:20 -28.
32. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 2002;3:753-766.
33. Scamuffa N, Calvo F, Chrétein M, Seidah NG, Khatib AM. Proprotein convertases: lessons learned from knockouts. FASEB J. 2006; 20:1954-1963.
34. Taylor NA, Van de Ven WJM, Creemers JWM. Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J. 2003;17:1215-1227.
35. Seidah NG, Mayer G, Zaid A, et al. The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol. 2008;40:1111-1125.
36. Fugere M, Appel J, Houghten RA, Lindberg I, Day R. Short poly-basic peptide sequences are potent inhibitors of PC5/6 and PC7: use of positional scalling-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol Pharmacol. 2007;71:323-332.
37. Fu X, Parks WC, Heinecke JW. Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol. 2008;19:2-13.
38. Dong Z, Ghabrial M, Katar M, Fridman R, Berk RS. Membrane-type matrix metalloproteinases in mice intracorneally infected with Pseudomonas aeruginosa. Invest Ophthalmol Vis Sci. 2000;41: 4189-4194.
39. Dong Z, Katar M, Alousi S, Berk RS. Expression of membrane-type matrix metalloproteinases 4, 5, and 6 in mouse corneas infected with P. aeruginosa. Invest Ophthalmol Vis Sci. 2001;42:3223-3227.
40. McClellan SA, Huang X, Barrett RP, et al. Matrix metalloproteinase-9 amplifies the immune response to Pseudomonas aeruginosa corneal infection. Invest Ophthalmol Vis Sci. 2006;47:256-264.
41. Ikema K, Matsumoto K, Inomata Y, et al. Induction of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs correlates with outcome of acute experimental pseudmonal keratitis. Exp Eye Res. 2006;83:1396-1404.
42. McIntosh RS, Cade JE, Al-Abed M, et al. The spectrum of antimicrobial peptide expression at the ocular surface. Invest Ophthalmol Vis Sci. 2005;46:1379-1385.